Abstract
Purpose. To study the interaction of the polyene antifungal amphotericin B with phospholipid Langmuir monolayers and to correlate with stability of phospholipid-stabilized drug emulsions.
Methods. Pressure—area isotherms of mixed monolayers of amphotericin B (0–20 mol%) and different phospholipid types were recorded using conventional Langmuir trough methods. Emulsion stability of amphotericin B-containing lipid emulsions was measured using dynamic light scattering.
Results. Incorporation of amphotericin B into monolayers composed of saturated phospholipids (Lipoid E80-3) had a profound effect on the shape of the isotherm. This effect was directly related to the concentration of amphotericin B in the monolayer. At high drug concentrations, the shape of the isotherms became progressively similar to that of pure DPPC, thus exhibiting regions attributable to phospholipid in different phase states. This effect on isotherm shape was not observed following incorporation of the drug into monolayers composed of the equivalent unsaturated lecithin (Lipoid E80).
Conclusions. These results are interpreted as indicating the formation of an amphotericin B-phospholipid complex, resulting in phase separation within the monolayer. The extent and nature of this phase separation was dependent on both the concentration of drug in the system, and the saturation state of the phospholipid component. The relevance of these observations to the stability of amphotericin B drug emulsions stabilised by saturated and unsaturated phospholipid emulsifiers is discussed. These observations may also be relevant to the toxicity of these, and other novel amphotericin B formulations.
Similar content being viewed by others
REFERENCES
H. A. Gallis, R. H. Drew, and W. W. Pickard. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308–329 (1990).
P. D. Hoeprich. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. J. Clin. Infect. Dis. 14 (Suppl. 1), S114–S119 (1992).
M. A. Carlson and R. E. Condon. Nephrotoxicity of amphotericin B. J. Amer. Coll. Surg. 179:361–381 (1994).
J. P. Adler-Moore and R. T. Proffitt. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Lipos. Res. 3:429–450 (1993).
L. S. S. Guo and P. K. Working. Complexes of amphotericin B and cholesteryl sulfate. J. Lipos. Res. 3:473–490 (1993).
A. S. Janoff, W. R. Perkins, S. L. Saletan, and C. E. Swenson. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J. Lipos. Res. 3:451–471 (1993).
R. C. C. New. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 8:371–381 (1981).
N. I. Payne, R. F. Cosgrove, A. P. Green, and L. Liu. Formulation aspects of proliposomes: in-vivo studies of liposomes containing amphotericin B. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 12:276–277 (1985).
N. I. Payne, R. F. Cosgrove, A. P. Green, and L. Liu. In-vivo studies of amphotericin B liposomes derived from proliposomes: effect of formulation on toxicity and tissue distribution of the drug in mice. J. Pharm. Pharmacol. 39:24–28 (1987).
R. L. Juliano, C. W. M. Grant, K. R. Barber, and M. P. Kalp. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol. Pharmacol. 31:1–11 (1987).
F.C. Szoka, D. Milholland, and M. Barza. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 31:421–429 (1987).
V. Joly, J. Bolard, L. Saint-Julien, C. Carbon, and P. Yeni. Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipidassociated amphotericin B formulations. Antimicrob. Agents Chemother. 36:262–266 (1992).
C. Washington and S. S. Davis. Nottingham University European Patent Application No. 90913513.9 (1991).
C. Washington, S. J. Taylor, and S. S. Davis. The structure of colloidal formulations of amphotericin B. Int. J. Pharm. 46:25–30 (1988).
D. Forster, C. Washington, and S. S. Davis. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. Pharm. Pharmacol. 40:325–328 (1988).
M. R. Lance, C. Washington, and S. S. Davis. Structure and toxicity of amphotericin B/triglyceride emulsion formulations. J. Antimicrob. Chemother. 36:119–128 (1995).
K. A. Lamb, C. Washington, S. S. Davis, and S. P. Denyer. Toxicity of amphotericin B emulsion to cultured canine kidney cell monolayers. J. Pharm. Pharmacol. 43:522–524 (1991).
C. Washington, O. Lutz, and S. S. Davis. Stability of an amphotericin B emulsion formulation. J. Pharm. Pharmacol. 43:93P (1991).
C. Washington and S. S. Davis. The production of parenteral feeding emulsions by Microfluidizer. Int. J. Pharm. 44:169–176 (1988).
C. Washington. The stability of intravenous fat emulsions in total parenteral nutrition mixtures. Int. J. Pharm. 66:1–21 (1990).
R. A. Hann. Molecular structure and monolayer properties. In G. Roberts (Ed.), Langmuir-Blodgett films, Plenum Press, New York, 1990, pp. 19–20.
H. E. Ries, M. Matsumoto, N. Uyeda, and E. Suito. Electron micrographs of cholesterol monolayers. J. Colloid. Interface Sci. 57:396–398 (1976).
O. Albrecht, H. Gruler, and E. Sackmann. Polymorphism of phospholipid monolayers. J. Phys. (Paris) 39:301–313 (1978).
M. E. Losche, E. Sackmann, and H. Mohwald. A fluorescence microscopic study concerning the phase diagram of phospholipids. Ber. Bunsenges. Phys. Chem. 87:848–852 (1983).
R. Peters and K. Beck. Translational diffusion in phospholipid monolayers measured by fluorescence microphotolysis. Proc. Nat. Acad. Sci. USA 80:7183–7187 (1983).
H. M. McConnell, L. K. Tamm, and R. M. Weis. Periodic structures in lipid monolayer phase transitions. Proc. Nat. Acad. Sci. USA 81:3249–3253 (1984).
L. K. Tamm, and H. M. McConnell. Supported phospholipid bilayers. Biophys. J. 47:105–113 (1985).
S. Benita and M. Y. Levy. Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterisation. J. Pharm. Sci. 82:1069–1079 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lance, M.R., Washington, C. & Davis, S.S. Evidence for the Formation of Amphotericin B-phospholipid Complexes in Langmuir Monolayers. Pharm Res 13, 1008–1014 (1996). https://doi.org/10.1023/A:1016046321726
Issue Date:
DOI: https://doi.org/10.1023/A:1016046321726